This research develops a novel nanozyme to effectively manage psoriasis, suggesting a new design paradigm for therapies against oxidative stress.
Psoriasis is a chronic inflammatory skin disease driven by oxidative stress, necessitating advanced antioxidant nanozymes capable of broad‐spectrum reactive oxygen species (ROS) elimination. Here, we address this challenge through the rational design of a ternary synergistic nanocluster, Ag 14–20 Au 5–11 @FeTP, engineered via “atomic engineering” of an optimal AgAu alloy core and “molecular engineering” via Fe‑porphyrin ligand grafting. This dual‐level engineering creates a metal–ligand synergistic interface that confers excellent multi‐enzyme mimetic activity for scavenging H 2 O 2 , •O 2 − , and •OH. Coupled with enhanced skin penetration, the nanozyme demonstrates both therapeutic and preventive efficacy in a psoriasis mouse model, rivaling the first‐line clinical drug betamethasone/calcipotriol, without observable systemic toxicity. Transcriptomic profiling reveals that its potent effect originates from a dual‐pathway immunomodulation: simultaneous suppression of the pro‐inflammatory IL‑23/Th17/IL‑17 and NF‑κB axes and enhancement of the anti‐inflammatory Treg/Th2 pathways. This work establishes a generalizable “precision synergy” paradigm for designing high‐performance nanocluster‐based therapeutics against oxidative stress‐related inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: